source
- BMS flags liver injury cases, including a death, in Phase 3 trial of pulmonary fibrosis drug admilparantBristol Myers Squibb has amended the protocol for its Phase 3 pulmonary fibrosis study of admilparant after reporting several liver injury events, one of which resulted in a patient death. The comp…
- Foghorn Therapeutics cuts 40% of workforce after ending Lilly oncology partnershipFoghorn Therapeutics and Eli Lilly announced the end of their 2021 oncology collaboration. The partnership had focused on developing and commercializing cancer treatments. Following the terminatio…